Course and prognosis in early-onset MS: comparison with adult-onset forms
- PMID: 12499484
- DOI: 10.1212/01.wnl.0000036907.37650.8e
Course and prognosis in early-onset MS: comparison with adult-onset forms
Abstract
Objectives: To establish the prognostic role of clinical and demographic factors in a hospital-based cohort of MS patients categorized by age at clinical onset and clinical course.
Methods: Eighty-three patients with MS had a clinical onset of the disease in childhood (age <16 years; early-onset MS [EOMS]) and 710 in adult age (between 16 and 65 years; adult-onset MS [AOMS]). Patients were followed for a mean period of observation of 5 years. Univariate and multivariate analyses of clinical and demographic predictors for rapid progression and disability were performed using a stepwise Cox regression model with time-dependent covariates.
Results: In EOMS, the Expanded Disability Status Scale (EDSS) evaluated at last clinical examination was lower than in AOMS, despite a longer disease duration. The probability to reach growth disability and progression was significantly lower in EOMS than in AOMS. Median times to reach EDSS score of 4 and secondary progression were longer in EOMS than in AOMS, but the age at both endpoints was significantly lower in EOMS. In EOMS and AOMS, an irreversible disability was related to a secondary progressive course, a sphincteric system involvement at onset, and an older age at onset (in EOMS only for the group >14 years); in AOMS, other unfavorable factors were a pyramidal involvement at onset and a high relapse frequency in the first 2 years. The risk of entering secondary progression was significantly influenced by a high number of relapses in EOMS and by a higher age at onset and a short interattack interval in AOMS.
Conclusion: A slower rate of progression of disease characterized EOMS patients, suggesting more plasticity to recover in developing CNS, but the early clinical manifestation cannot be considered a positive prognostic factor.
Similar articles
-
Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population.Clin Neurol Neurosurg. 2007 Jan;109(1):32-7. doi: 10.1016/j.clineuro.2006.06.002. Epub 2006 Jul 25. Clin Neurol Neurosurg. 2007. PMID: 16870328
-
Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis.J Clin Med. 2020 May 2;9(5):1326. doi: 10.3390/jcm9051326. J Clin Med. 2020. PMID: 32370288 Free PMC article.
-
Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.Clin Neurol Neurosurg. 2023 Jan;224:107528. doi: 10.1016/j.clineuro.2022.107528. Epub 2022 Nov 23. Clin Neurol Neurosurg. 2023. PMID: 36446265
-
Mitoxantrone: a review of its use in multiple sclerosis.CNS Drugs. 2004;18(6):379-96. doi: 10.2165/00023210-200418060-00010. CNS Drugs. 2004. PMID: 15089110 Review.
-
Disability profile of MS did not change over 10 years in a population-based prevalence cohort.Neurology. 2004 Feb 24;62(4):601-6. doi: 10.1212/wnl.62.4.601. Neurology. 2004. PMID: 14981177 Review.
Cited by
-
Impact of race and socioeconomic deprivation on clinical outcomes and healthcare utilization in pediatric multiple sclerosis.Mult Scler J Exp Transl Clin. 2024 Aug 26;10(3):20552173241274586. doi: 10.1177/20552173241274586. eCollection 2024 Jul-Sep. Mult Scler J Exp Transl Clin. 2024. PMID: 39193072 Free PMC article.
-
Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.Mult Scler. 2024 Jun;30(7):833-842. doi: 10.1177/13524585241242050. Epub 2024 Apr 15. Mult Scler. 2024. PMID: 38619037 Free PMC article. Clinical Trial.
-
Prognosis in meningoencephalitis of unknown origin in dogs: Risk factors associated with survival, clinical relapse, and long-term disability.J Vet Intern Med. 2024 May-Jun;38(3):1583-1590. doi: 10.1111/jvim.17037. Epub 2024 Mar 14. J Vet Intern Med. 2024. PMID: 38483069 Free PMC article.
-
Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis.Heliyon. 2024 Feb 17;10(4):e26658. doi: 10.1016/j.heliyon.2024.e26658. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38420491 Free PMC article.
-
Incidence rate and prevalence of pediatric-onset multiple sclerosis in Sweden: A population-based register study.Eur J Neurol. 2024 May;31(5):e16253. doi: 10.1111/ene.16253. Epub 2024 Feb 18. Eur J Neurol. 2024. PMID: 38369806 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical